Westlake Village BioPartners today announced it participated in the $75 million Series B financing of Tmunity Therapeutics, a company focused on delivering the full potential of next-generation T cell immunotherapy.
Westlake Village BioPartners is pleased to have seeded and been a major contributor to the Series A funding round for programmable cell therapy company Arsenal Biosciences. The company will integrate technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies, initially for cancer.
At the recent Healthcare Businesswomen’s Association meeting, several themes emerged as essential ingredients in building the Los Angeles biotech hub. Westlake Village BioPartners’ managing director Sean Harper participated in a panel discussion that examined the issues facing Los Angeles as it grows its life sciences industry. The event, titled “Los Angeles: The Next Major Biotechnology … Read More
Los Angeles has a long history of reinventing itself. From a village of 5,000 people in the 1870s, focused on cattle farming and agriculture; to establishing ports, railways, banks and factories designed to challenge San Francisco; to producing one-quarter of the world’s total oil supply by 1923; to the boomtown days of Hollywood from 1913-1941; … Read More